Joint Formulary & PAD

Salbutamol (Salbulin Novolizer) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Inhaler (dry powder)
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Salbutamol (Salbulin Novolizer)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
SABA
Keywords :
Salbutamol inhalers, SABAs, bronchodilators, adrenoreceptor agonists, short acting beta 2 agonist, respiratory
Brand Names Include :
Salbulin Novolizer
Important Information :

Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.

Not for initiation in new patients.

Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
2

Other Indications

Below are listed other indications that Salbutamol (Salbulin Novolizer) is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (1)

The locally preferred salbutamol devices are as follows:

Low carbon:

  • Salbutamol Easyhaler (dry powder inhaler)
  • Ventolin Accuhaler (dry powder inhaler)

Alternative devices:

  • Salamol (MDI) is the locally preferred salbutamol metered dose inhaler device and should be used with a spacer device. It has a lower carbon footprint than the large volume MDIs such as Ventolin.
  • Ventolin Evohaler (MDI) 

Branded prescribing of inhaler devices is recommended.

See local COPD guidelines for more information